603
26.4.3 Pharmacology
Recombinant technology is a current technique utilized for the production of therapeutic agents. Drugs produced by recombinant technology are recognized as genetically engineered drugs, recombinant DNA expressed products, biopharmaceuticals,
and biologics (Baeshen et al. 2016). Recombinant pharmacology products are factor
VIII, tumor necrosis factor, superoxide dismutase, enzymes, insulin, coagulation
modulators, growth hormone, granulocyte colony stimulating factors, GM-CSF,
anti-rheumatoid drugs, erythropoietin, transforming growth factors, platelet-derived
growth factors, fibroblast, interleukins, and interferon (Kishore and Krishan 2009).
Biotechnologists also seek to identify cancer-causing genes known as oncogenes.
Tumor suppressor genes get special attention to make proteins by encoding these
genes to make drugs that inhibit cancer cell growth (Zhu et al. 2015).
26.4.4 Medicine
Recombinant DNA technology places genetics in the mainstream of medicine
(Olson 2017). A genetic testing will provide us great information from common to
rare diseases of humans (Qiao et al. 2017). This technology is used to identify and
allocate faulty gene loci (Jin et al. 2017). Genetic probes are used to diagnose the
disease in its early stage as well as to determine its probability in future generations
(Kelley 2017). The knowledge of disease is advanced due to the discovery of methods for diagnosing gene defects (Wright et al. 2017). Recombinant DNA technology also helps humankind in the treatment of many diseases, which could be
difficult or impossible to treat. Some common methods are in vivo and ex vivo
(Santangelo et al. 2017). Gene therapy, antiviral therapy, recombinant vaccination,
synthesizing clotting factors, fluorescent fishes, glowing plants, development of
diagnostic proteins etc.; are different examples. Salmonella-specific biotinylated
DNA probe has been developed for fast routine recognition of Salmonella. Stem
cell technology is also utilized in enhancing the growth (regeneration) of damaged
organs. Many recombinant proteins that are synthesized by manipulating DNA are
now being used for the treatment of diseases. Protein engineering has been utilized
to develop second-generation variants with better pharmacokinetics, structure,
strength, and bioavailability. For instance, in the neutral solutions used for treatment, insulin is frequently assembled as zinc-containing hexamers. Absorption is
however limited by this self-association. By creating single amino acid replacements, nowadays, molecular biologists are capable to make insulin that is fundamentally monomeric at therapeutic concentrations. This insulin has been discovered
to not only be able conserve their biological action but more effectively absorbed by
2–3 times. Few years ago, scientists have recognized that all therapeutics will not be
effective for all patients due to their different immune system responses. Presently
however, new research and technologies have been made to enhance the identification
26 Genetic Engineering of Novel Products of Health Significance: Recombinant DNA…
26.4.3 Pharmacology
Recombinant technology is a current technique utilized for the production of therapeutic agents. Drugs produced by recombinant technology are recognized as genetically engineered drugs, recombinant DNA expressed products, biopharmaceuticals,
and biologics (Baeshen et al. 2016). Recombinant pharmacology products are factor
VIII, tumor necrosis factor, superoxide dismutase, enzymes, insulin, coagulation
modulators, growth hormone, granulocyte colony stimulating factors, GM-CSF,
anti-rheumatoid drugs, erythropoietin, transforming growth factors, platelet-derived
growth factors, fibroblast, interleukins, and interferon (Kishore and Krishan 2009).
Biotechnologists also seek to identify cancer-causing genes known as oncogenes.
Tumor suppressor genes get special attention to make proteins by encoding these
genes to make drugs that inhibit cancer cell growth (Zhu et al. 2015).
26.4.4 Medicine
Recombinant DNA technology places genetics in the mainstream of medicine
(Olson 2017). A genetic testing will provide us great information from common to
rare diseases of humans (Qiao et al. 2017). This technology is used to identify and
allocate faulty gene loci (Jin et al. 2017). Genetic probes are used to diagnose the
disease in its early stage as well as to determine its probability in future generations
(Kelley 2017). The knowledge of disease is advanced due to the discovery of methods for diagnosing gene defects (Wright et al. 2017). Recombinant DNA technology also helps humankind in the treatment of many diseases, which could be
difficult or impossible to treat. Some common methods are in vivo and ex vivo
(Santangelo et al. 2017). Gene therapy, antiviral therapy, recombinant vaccination,
synthesizing clotting factors, fluorescent fishes, glowing plants, development of
diagnostic proteins etc.; are different examples. Salmonella-specific biotinylated
DNA probe has been developed for fast routine recognition of Salmonella. Stem
cell technology is also utilized in enhancing the growth (regeneration) of damaged
organs. Many recombinant proteins that are synthesized by manipulating DNA are
now being used for the treatment of diseases. Protein engineering has been utilized
to develop second-generation variants with better pharmacokinetics, structure,
strength, and bioavailability. For instance, in the neutral solutions used for treatment, insulin is frequently assembled as zinc-containing hexamers. Absorption is
however limited by this self-association. By creating single amino acid replacements, nowadays, molecular biologists are capable to make insulin that is fundamentally monomeric at therapeutic concentrations. This insulin has been discovered
to not only be able conserve their biological action but more effectively absorbed by
2–3 times. Few years ago, scientists have recognized that all therapeutics will not be
effective for all patients due to their different immune system responses. Presently
however, new research and technologies have been made to enhance the identification
26 Genetic Engineering of Novel Products of Health Significance: Recombinant DNA…